The limitations in scientific research and clinical application of these biomarkers are mainly related to the variability of results across different studies, the low specificity and sensitivity of CA125, the scarcity of data regarding HE4 in gynecologic tumors, and the complete absence of data on the use of HE4 in uterine sarcomas. The gene discussed is MUC16; the disease is uterine corpus sarcoma.